You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物-B(01877.HK):科創板上市申請審核狀態為“已問詢”
格隆匯 01-21 17:56

格隆匯1月21日丨君實生物-B(01877.HK)發佈公告,公司已上交所提交了首次公開發行股票並在科創板上市的申請,並於2019年9月26日收到了上交所出具的上證科審(受理)[2019]159號《關於受理上海君實生物醫藥科技股份有限公司首次公開發行股票並在科創板上市申請的通知》,公司首次公開發行股票並在科創板上市的申請已獲得上交所的正式受理。

目前,公司首次公開發行股票並在科創板上市申請的審核狀態為“已問詢”。根據《全國中小企業股份轉讓系統業務規則(試行)》的規定,公司股票將繼續在全國中小企業股份轉讓系統暫停轉讓。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account